Key result
Left atrial appendage closure with the Watchman FLX system was safely performed in a hemodialysis patient with hypertrophic cardiomyopathy and atrial fibrillation, without subsequent thrombotic events.
Why the study?
Anticoagulation is recommended for hypertrophic cardiomyopathy with atrial fibrillation, but is not recommended for patients requiring hemodialysis due to high bleeding risk.
Case Report (n=1)
No
Answers are grounded in this paper and cite their sources.
LAAC with the Watchman FLX system may serve as a viable alternative to anticoagulation for stroke prevention in patients with dilated phase HCM and atrial fibrillation who are on hemodialysis and at high bleeding risk.
Patients with hypertrophic cardiomyopathy (HCM) often have atrial fibrillation, and empiric anticoagulation is recommended in these patients, regardless of other risk factors. However, anticoagulation is not recommended for patients who require hemodialysis (HD) because of the high bleeding risk. We herein report a case of left atrial appendage closure (LAAC) using the Watchman FLX system for a dilated phase HCM patient complicated by persistent atrial fibrillation and requiring HD. LAAC with the Watchman FLX system may be an alternative to antithrombotic medications in patients with dilated HCM complicated by atrial fibrillation and requiring HD.
No takes yet. Share an insight, caveat, or question.
Funaki et al. (2023) conducted a case report in Hypertrophic cardiomyopathy with atrial fibrillation and end-stage renal failure on hemodialysis (n=1). Left atrial appendage closure with the Watchman FLX system was evaluated on Procedural success and clinical outcomes (thrombotic or bleeding events). Left atrial appendage closure with the Watchman FLX system was safely performed in a hemodialysis patient with hypertrophic cardiomyopathy and atrial fibrillation, without subsequent thrombotic events.
Synapse has enriched 10 related papers. Consider them for comparative context: